Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Hepatitis C virus NS3/4a protease inhibitor
Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively.- Deqiang Kong, .et al. , Nat Commun, 2024, Jun 8;15(1):4894 PMID: 38849338
- Xinyi Wang, .et al. , Nat Chem Biol, 2023, Oct 23 PMID: 37872400
-
Bcr-Abl inhibitor
Imatinib mesylate, a selective tyrosine kinase inhibitor, induced a sustained objective response in treating gastrointestinal stromal tumors with the inhibition of the KIT signal-transduction pathway.- Inge Govaerts, .et al. , J Hematol Oncol, 2021, 14: 97 PMID: 34167562
- Genevra Kuziel, .et al. , Cancers (Basel), 2020, Jul 28;12(8):E2083 PMID: 32731354
-
PDGFR inhibitor
Imatinib (Gleevec) is a number of tyrosine kinase enzymes specific inhibitor.- Rong Zhang, .et al. , Gene, 2024, Jan 30:893:147917 PMID: 37866664
- Aya Hasan Alshammari, .et al. , Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
- Takafumi Shima, .et al. , Oncol Rep, 2022, 47: 7 PMID: 34738628
- Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
- BM Duggan, .et al. , Endocrinology, 2020, May 30;bqaa086 PMID: 32473019
- Li Li, .et al. , Leukemia Res, 2019, 78:12-20 PMID: 30660961
- Brittany M. Duggan, .et al. , Sci Rep, 2017, 7: 1578 PMID: 28484277
-
RdRp inhibitor
Galidesivir hydrochloride (BCX 4430 hydrochloride) is a viral RNA-dependent RNA polymerase (RdRp) inhibitor; demonstrated broad-spectrum activity in multiple viruses and a favorable preliminary preclinical safety profile. -
S100A9 inhibitor
Paquinimod is a S100A9 inhibitor, which prevents S100A9 binding to TLR-4. -
SARS-CoV PLpro Inhibitor
4'-O-Methylbavachalcone is a prenylated flavonoid that acts as an inhibitor of the SARS-CoV papain-like protease (PLpro), displaying an IC50 value of 10.1 μM and a Ki of 4.6 μM. This compound has demonstrated the ability to inhibit poly (ADP-ribose) polymerase-mediated cell death and reduce cerebral infarct volume. Additionally, it modulates SUCNR1 activity and interferes with ERK1/2 signaling pathways, affecting cardiomyocyte hypertrophy. 4'-O-Methylbavachalcone is applicable in research focused on ischemic stroke, SARS-CoV, and cardiovascular diseases. -
SARS-CoV-2 RdRp Inhibitor
RdRP-IN-10 is a selective inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), exhibiting an IC50 of 5.78 μM. This compound covalently binds to Cys114 of the SARS-CoV-2 nsp8 protein, disrupting the stabilizing interactions between nsp8 and nsp12. RdRP-IN-10 effectively inhibits RNA polymerization mediated by RdRp without interfering with the RNA-RdRp complex formation. It demonstrates antiviral activity in cellular models and serves as a valuable tool for researching SARS-CoV-2 infection mechanisms and potential therapeutic interventions. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-115 is a potent inhibitor of SARS-CoV-2, demonstrating significant antiviral activity in infected Calu-3 cells with an EC50 of 1.7 μM. This compound effectively inhibits human dihydroorotate dehydrogenase (HsDHODH) with an IC50 of 1.5 μM. Notably, SARS-CoV-2-IN-115 preserves immune response without exhibiting antiproliferative effects on CD4 T cells, making it a valuable tool for research in antiviral therapeutics and immune modulation. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-113 is a sulfonohydrazide derivative designed to inhibit SARS-CoV-2 infection, demonstrating an IC50 of 8.320 μM. This compound exerts significant antiviral activity by blocking viral entry and replication, while also downregulating the expression of key genes and proteins such as Spike, ACE-2, and RdRp. With its high selectivity and low cytotoxicity, SARS-CoV-2-IN-113 serves as a valuable tool for research in the field of SARS-CoV-2 biology and therapeutic development. -
SARS-CoV-2 Inhibitor
TFMU-ADPr is a selective reporter substrate that targets the SARS-CoV-2 Macro1 protein, displaying an IC50 of 0.59 μM. This compound emits fluorescence at 502 nm (or 495 nm) upon enzymatic hydrolysis by Poly(ADP-ribose) Glycohydrolase (PARG) and ADP-ribosylhydrolase 3. TFMU-ADPr binds to the ADPr-binding site of Macro1, providing a robust method for assessing the activity of poly(ADP-ribose) hydrolases. Its applications extend to evaluating small-molecule inhibitors under in vitro conditions, investigating ADP-ribosyl catabolic enzyme mechanisms, and detecting PAR hydrolase activity in whole-cell lysates, making it a valuable tool for COVID-19-related research. -
SARS-CoV Inhibitor
Direct Violet 1 is an azo dye that functions as an inhibitor of the spike protein-ACE2 interaction in SARS-CoV-2, exhibiting IC50 values ranging from 1.47 to 2.63 μM. This compound serves as a valuable tool for investigating viral entry mechanisms and studying protein-protein interactions related to SARS-CoV-2. Its application may extend to antiviral research and the development of therapeutic strategies targeting COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 nsp14-IN-3 is an inhibitor of the SARS-CoV-2 N7-Methyltransferase, demonstrating an IC50 value of 3.5 μM. This compound is designed to interfere with the viral methylation process, which is crucial for viral replication and evasion of host immune responses. It serves as a valuable tool in antiviral research and the development of therapeutic strategies targeting SARS-CoV-2. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-7 is a potent inhibitor of the SARS-CoV virus, demonstrating significant antiviral activity with an IC50 value of 844 nM in SARS-CoV-2-infected Vero E6 cells. This compound is primarily utilized in research applications aimed at understanding viral replication processes and developing effective therapeutics against SARS-CoV-2. Its efficacy makes it a valuable tool for studying COVID-19 and potential antiviral strategies. -
SARS-CoV Inhibitor
Bonducellpin D is a furanoditerpenoid lactone that acts as an inhibitor of SARS-CoV and MERS-CoV main proteases (Mpro). With Ki values of 467.11 nM and 284.86 nM for SARS-CoV and MERS-CoV, respectively, it demonstrates broad-spectrum antiviral activity. Additionally, Bonducellpin D exhibits moderate anti-cancer activity in vitro, making it a valuable compound for research into both viral inhibition and cancer therapeutics. -
SARS-CoV Inhibitor
SSAA09E3 is a SARS-CoV entry inhibitor that effectively blocks the entry of SARS/HIV pseudotyped viruses, demonstrating an EC50 of 9.7 μM in 293T cells. Additionally, it has shown significant antiviral activity against SARS-CoV infection in Vero cells, with an EC50 of 0.15 μM. This compound is valuable for research applications aimed at understanding viral entry mechanisms and developing antiviral strategies against SARS-CoV. -
SARS-CoV-2 Inhibitor
AT-9010 triethylamine is a tri-phosphate active metabolite of AT-527 that functions as a potent inhibitor of the NiRAN enzyme, an essential target for viral replication in SARS-CoV-2. It exhibits significant antiviral activity by effectively inhibiting the replication of SARS-CoV-2, making it a valuable tool for research on COVID-19 and potential therapeutic strategies against coronavirus infections. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-15 is a potent inhibitor of SARS-CoV-2, exhibiting an IC50 of 0.49 μM. This niclosamide analogue demonstrates enhanced stability in human plasma and liver S9 enzyme assays compared to its predecessor, which may improve its bioavailability and half-life upon oral administration. SARS-CoV-2-IN-15 is suitable for research applications focused on antiviral drug development and the elucidation of SARS-CoV-2 infection mechanisms. -
SARS-CoV-2 Inhibitor
Cleistanthin B is a potent inhibitor of SARS-CoV-2, demonstrating anti-viral activity with an EC50 of 6.51 µM in Vero cells. This orally active arylnaphthalene lignan lactone glycoside also exhibits notable antitumor, diuretic, and antihypertensive properties in vivo, making it a versatile compound for various research applications in virology and pharmacology. -
SARS-CoV-2 PLpro Inhibitor
GZNL-P36 is a potent inhibitor of SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 6.45 nM, demonstrating effective inhibition of SARS-CoV and its variants with EC50 values ranging from 58.2 nM to 2.66 µM. In pharmacokinetic studies conducted in CD-1 mice, GZNL-P36 achieved a peak plasma concentration (Cmax) of 549 ng/mL, a half-life (T1/2) of 1.45 hours, and a bioavailability of 74.7%. This compound exhibits notable antiviral activity in SARS-CoV-2 XXB.1 infections, positioning it as a valuable tool in therapeutic research against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-78 is an inhibitor of the nsp14 protein of SARS-CoV-2, specifically targeting its N7 methyltransferase activity. This compound demonstrates significant antiviral properties and is valuable for research applications in understanding and mitigating SARS-CoV-2 infection. Its mechanism of action makes it a pertinent tool for studying viral replication and pathogenesis, as well as the development of potential therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
ZINC000104379474 is a potent inhibitor of SARS-CoV-2 endoribonuclease. It exhibits significant antiviral activity, making it a valuable tool in the study of SARS-CoV-2 replication mechanisms. This compound is particularly relevant for research focused on COVID-19 therapeutics and the development of novel antiviral strategies. -
SARS-CoV-2 Nsp14 Inhibitor
SARS-CoV-2 nsp14-IN-2 is a selective inhibitor of SARS-CoV-2 Nsp14 methyltransferase, exhibiting an IC50 value of 0.093 µM. This compound demonstrates significant antiviral activity and is stable in plasma and liver S9 fractions. SARS-CoV-2 nsp14-IN-2 is valuable for research applications focusing on COVID-19 and the exploration of therapeutic strategies targeting viral replication mechanisms. -
SARS-CoV Inhibitor
SARS-CoV MPro-IN-1 is a covalent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 40 nM. This compound demonstrates significant anti-SARS-CoV-2 activity in cell culture, with an EC50 of 0.33 μM. SARS-CoV MPro-IN-1 is suitable for research applications focused on COVID-19 and related viral pathogenesis. -
SARS-CoV-2 Inhibitor
10-Hydroxyaloin A is a potent inhibitor of SARS-CoV-2, specifically targeting the main protease (Mpro) of the virus. This compound demonstrates significant binding affinity to the active site of Mpro, which is crucial for viral replication. 10-Hydroxyaloin A is of particular interest in research applications focused on antiviral drug development and understanding the mechanisms of SARS-CoV-2 inhibition. -
SARS-CoV-2 3CLpro Inhibitor
3CPLro-IN-1 is a potent, orally active inhibitor of the SARS-CoV-2 3CLpro with an IC50 of 5.65 μM. 3-Chymotrypsin-like cysteine protease (3CLpro) plays a critical role in viral replication, making it a significant target for therapeutic intervention against COVID-19. This compound is suitable for research applications focused on developing antiviral strategies and studying the mechanistic pathways of viral replication. -
SARS-CoV-2 Inhibitor
Amb929 is a selective inhibitor targeting the nsp3 protein of SARS-CoV-2, demonstrating significant antiviral activity. It effectively inhibits SARS-CoV-2-mNG replication in VeroE6 cells with an EC50 of 34.7 µM and has a moderate cytotoxicity profile, with a CC50 of 281 µM. Additionally, Amb929 shows effectiveness in suppressing viral replication in Human Airway Epithelium (HAE) models, making it a valuable tool for research on COVID-19 and therapeutic development. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2-IN-35 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrating a Ki value of 12.1 nM. This compound serves as a valuable tool for investigating the antiviral mechanisms and therapeutic strategies in COVID-19 research. Its oral bioactivity allows for flexible in vivo studies, facilitating the exploration of potential treatments against SARS-CoV-2. -
SARS-CoV-2Inhibitor
SARS-CoV-2-IN-43 is a potent inhibitor of SARS-CoV-2 replication, displaying significant antiviral activity. This compound is valuable for research applications aimed at understanding and mitigating SARS-CoV-2 infection. Its mechanism of action targets key processes in viral replication, making it a crucial tool for studies in virology and therapeutic development against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
AB-343 is a selective covalent inhibitor targeting the main protease (Mpro) of SARS-CoV-2, exhibiting an IC50 of 8 nM and a Ki of 2.8 nM. This compound effectively inhibits the Mpro of SARS-CoV-2 and other coronaviruses, demonstrating activity against certain resistant variants. AB-343 is suitable for research applications focused on therapeutic strategies for coronavirus infection-related diseases. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-1 (compound 16b-3) is a potent and selective irreversible inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrated by an IC50 of 116 nM. This compound serves as a valuable tool in research targeting SARS-CoV-2, facilitating investigations into viral replication and pathogenesis. Its mechanistic profile makes it suitable for studies aimed at developing antiviral strategies against COVID-19. -
SARS-CoV-2 Mpro Iinhibitor
GC-78-HCl is a nonpeptidic inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 0.19 μM. This compound demonstrates significant antiviral activity and has been characterized by favorable pharmacokinetic properties. It is a valuable reagent for research aimed at exploring therapeutic strategies against SARS-CoV-2 and related coronaviruses. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-66 is a vitamin K derivative and a potent inhibitor of SARS-CoV-2. It exhibits an EC50 value of 70.8 μM in Vero E6/TMPRSS2 cell lines, demonstrating significant antiviral activity. This compound can be utilized in research focused on the development of therapeutic strategies against SARS-CoV-2 infection. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-100 is a potent inhibitor targeting SARS-CoV-2, exhibiting broad-spectrum antiviral activity against multiple variants of the virus. This compound demonstrates synergistic effects when used in combination with Nirmatrelvir, potentially mitigating the risk of antiviral drug resistance. It is suitable for research applications focused on COVID-19 therapeutics and viral replication studies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-76 is a specific inhibitor of the nsp14 viral cap N7 methyltransferase and PLpro, targeting the severe acute respiratory syndrome coronavirus (SARS-CoV-2). This compound demonstrates significant antiviral activity by disrupting key enzymatic processes essential for viral replication. It is a valuable tool for research applications focused on understanding SARS-CoV-2 pathogenesis and developing therapeutic strategies against COVID-19. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2-IN-80 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 0.964 µM. This compound demonstrates strong antiviral activity, making it a valuable tool for research aimed at unraveling the mechanisms of SARS-CoV-2 replication and pathogenesis. It is suitable for studies focused on developing therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-75 is a chloroacetamide-based inhibitor targeting SARS-CoV-2. This compound demonstrates significant antiviral activity, inhibiting cellular replication of SARS-CoV-2 with an EC68 value of 3 μM. It is relevant for research applications focused on understanding viral mechanisms and developing therapeutic strategies against COVID-19. -
SARS-CoV-1/2 RdRp Inhibitor
SARS-CoV-IN-6 is a selective inhibitor of the RNA-dependent RNA polymerase (RdRp) of both SARS-CoV-1 and SARS-CoV-2, featuring an IC50 of 7.8 μM against SARS-CoV-2 RdRp. This compound effectively mitigates cytopathic effects in cells infected with SARS-CoV-1 and SARS-CoV-2 replicon-based single-round infectious particles (SRIPs). Additionally, it inhibits the expression of the SARS-CoV N protein, showing EC50 values of 0.12 µM for SARS-CoV-1 SRIPs and 1.47 µM for SARS-CoV-2 SRIPs. SARS-CoV-IN-6 is valuable for research focused on the antiviral mechanisms targeting coronavirus replication. -
SARS-CoV-2 Inhibitor
F8-S40 is a potent inhibitor of the SARS-CoV-2 main protease, demonstrating an IC50 of 10.88 μM. It exhibits significant antiviral activity, making it a valuable tool for researchers investigating COVID-19 therapies. This compound is suitable for studies focused on the inhibition of viral replication and the exploration of new therapeutic strategies against SAR-CoV-2. -
SARS-CoV-2 SP Inhibitor
SP Inhibitor 1 is a selective inhibitor of the SARS-CoV-2 spike protein, exhibiting an IC50 of 3.26 μM, while demonstrating minimal inhibition of Mpro and PLpro above 25 μM. This compound effectively inhibits SARS-CoV-2 replication in vitro at non-toxic concentrations ranging from 0.325 to 5.98 μM. SP Inhibitor 1 possesses significant cellular antiviral activity, making it a valuable tool for research applications focused on understanding and combating SARS-CoV-2. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-20 is a covalent inhibitor of the SARS-CoV-2 3CL protease, with an IC50 of 0.43 μM and a Ki value of approximately 0.33 μM. This compound is essential for investigating the inhibition of the viral protease, which plays a crucial role in the replication of SARS-CoV-2. It serves as a valuable tool in research focused on antiviral drug discovery and the development of therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 Mpro-IN-21 is a highly potent inhibitor of the SARS-CoV-2 Main Protease (MPro), targeting critical viral replication processes. This compound demonstrates significant antioxidant activity, with an IC50 of 0.36 mg/mL in the DPPH assay, indicating its potential in oxidative stress-related research. Furthermore, SARS-CoV-2 Mpro-IN-21 exhibits strong antibacterial activity against Klebsiella, with an IC50 of 1.19 mg/mL, making it a valuable tool for studies in viral and bacterial pathogenesis. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-32 is a selective inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 value of 230 nM. This compound effectively inhibits the replication of various SARS-CoV-2 variants in vitro, making it a valuable tool for studying the virus's biology and testing potential therapeutic strategies against COVID-19. Its specificity towards Mpro positions it as a significant candidate for further research in antiviral drug development. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-56 is a potent inhibitor of SARS-CoV-2, specifically targeting viral replication. This compound demonstrates significant antiviral activity, effectively inhibiting SARS-CoV-2 in Vero E6 cells with an IC50 value of 0.7 μM. It serves as a valuable reagent for research applications focused on understanding SARS-CoV-2 infection mechanisms and developing therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-22 is an inhibitor that targets the entry of SARS-CoV-2 pseudovirus into host cells, exhibiting an IC50 value of 16.96 µM. This compound is valuable for research applications focused on understanding viral entry mechanisms and developing therapeutic strategies against COVID-19. Its effective inhibition supports studies aimed at identifying potential antiviral agents and exploring host-pathogen interactions. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-35 is an inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 0.15 μM. This compound demonstrates potent anti-SARS-CoV-2 activity and effectively inhibits the proliferation of bladder cancer cells while maintaining low cytotoxicity in fibroblasts. It is suitable for research applications focused on SARS-CoV-2 infection and bladder cancer treatment strategies.
